| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Category | Name | Significant development 10th August - 24th August | Significant development 24th August to 8th September | See Note* | Company | Anticipated trial entry date | Description | Data | Funding received | Ref | |||||||||||||||||||||||||
2 | 16/03/2020 | Vaccine | mRNA-1723 | Moderna | March 2020 | mRNA vaccine. Have struck a deal with Lonza for mass scale manufacture. Moderna also have obtained "FDA Fast Track" in order to accelerate regulatory approval. They are aiming for Phase III trials in July 2020 (which was confirmed in early June) | First in human trial launched 16th March 2020. Interim results reported on the 18th May 2020 showing: - Overall safe and well tolerated - Patients developed antibodies that were equivalent titres to that seen in convalescent sera, and those on the higher dose of the vaccine developed antibody titres that exceeded titres seen in convalescent sera - Antibodies from 8 patients analysed thus far were shown to be neutralising in neutralisation assays against live virus - Mice challenge studies (pre-clinical) prevented viral replication in the lung - Plan to start pivotal phase III study in July Note: The above does not describe evidence that vaccinated individuals cannot get Covid-19 or fall ill, but provides a promising biomarker readout. On 13th June Moderna published a pre print showing the vaccine was protective in mice. In late August Moderna reported that the vaccine drives neutralising antibodies in elderly patients (55+) as well as younger adults | Partnership with BARDA worthup to $483M | https://www.bloomberg.com/news/articles/2020-03-13/roche-gets-clearance-for-coronavirus-test-that-s-10-times-faster https://www.fiercepharma.com/manufacturing/moderna-aims-for-a-billion-covid-19-shots-a-year-lonza-manufacturing-tie-up?mkt_tok=eyJpIjoiTjJVeE1XUTRNR014WTJabSIsInQiOiJIb25pd08yc29ZVnpiSEtGazN2d2s2XC9PR0xkaERFN2swejE3Q2x6Qm54Vkw1dUNHaEt6QVwvR2dyU2NaTmVlcld6VGtnbEJMY0RncTdPRWxzbDlaRHo4dkFpMEtjOHp6aGJvU0NhazVuTUd4V3hTaE1lS3pYTmZhczE0cG1SZ0lsNVZEXC8rWjYydjZqRVJwMkhpVTdSYkE9PSJ9&mrkid=114702534 https://www.fiercebiotech.com/biotech/moderna-nabs-fda-fast-track-tag-for-its-covid-19-vax https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine https://endpts.com/covid-19-roundup-hydroxychloroquine-fails-to-prevent-infection-in-study-beijing-arrests-ex-biogen-staffer-who-flew-while-infected/ | |||||||||||||||||||||||||||
3 | 18/03/2020 | Vaccine | ChAdOx1-nCov19 / AZD1222 | Oxford University Jenner Institute, Vaccitech & AstraZeneca | TBD | ChAdOx1 (Chimpanzee Adenovirus Vector) containing sequence for viral spike protein.On the 20th April it was announced that Oxford University and Vaccitech have entered a partnership with AZ for manufacture and scale up of the vaccine. UK Government announced £38 funding support for the vacccine manufacture on the 17th May 2020 in order to stockpile 30 million doses. On the 4th June it was announced AZ had reached a $750M with CEPI and GAVI to distribute 300 million doses of the vaccine by the end of 2020. AZ also agreed to a licensing deal with the Serum Institute of India to provide 1 billion doses of the vaccine to low- and middle-income countries, with the goal of 400 million produced by year's end. In total, the deals will bring AstraZeneca's overall supply capacity for Oxford's vaccine candidate to more than 2 billion doses per year. | Approach using the ChAdOx1 vector was used to design vaccine for MERS that has had some success in early clinical trials. Promising non human primate data showing 6 macaques immunised with the vaccine and then challenged with the virus did not develop pneumonia (pre-print published 14th May). First patients injected on 23rd April for a large scale Ph I / Ph II trial with no adverse effects reported so far. As of 22nd May 2020 it was reported that Oxford / AZ were beginning to recruit for the Phase II / III trial over 10,260 people. As of 29th May 2020 it was reported that the Phase II / III trial had commenced enrollment. As of mid June it was reported the team were planning a trial in Brazil where the incidence levels are higher in order to demonstrate efficacy. W/c 20th July Phase I trial results were published in the Lancet which were encouraging: "One dose was sufficient to elicit some antibody response in over 90% of people, and a second dose pushed it to 100%, at levels similar to what’s observed in convalescent patients. Spike-specific effectors T cells were observed “as early as day 7, peaking at day 14 and maintained up to day 56 as expected with adenoviral vectors.” | $1BN from BARDA, £65M from UK Government | https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development https://www.vaccitech.co.uk/vaccitech-and-oxford-university-announce-landmark-partnership-with-astrazeneca-for-the-development-and-large-scale-distribution-of-the-covid-19-vaccine-candidate/ https://www.biorxiv.org/content/10.1101/2020.05.13.093195v1 eyJpIjoiTmpjNVkySTFZVEk1TjJVNSIsInQiOiIyS21FWGVWN2F6RUlNc2M3NXRcL1wvS2d3VDlyQ2duZG9hSEVoVFl2Uk41elgyTkVuY0VLeE5ZSUl4ZWxnTFB0aFVDUDRoVEU0aStWcE1VdHRVQUxvTVpKWDNtTlZJTmZUVWlVUkNha1wvQ0Izb095Mm9Vbld1VGNqSGpIdGsyZXNYOENTUlVGM0pvNnNaU0dCbisyMEJYRmc9PSJ9 https://www.fiercebiotech.com/biotech/astrazeneca-s-covid-19-vaccine-enters-phase-2-3-clinical-trial?mkt_tok=eyJpIjoiTVRrd1lUVm1NelkyWVRkaCIsInQiOiJabTlOQnM3RlgxVENcL1JRXC9tbUdHMHJVZDhPcGpqWDBqWTQrTGttU3RtMkpkaDZZeXZ0NzVzXC9PKzhLczZFaUx0Y2lqblZBM1wvZlZtOUhBeEpZQkZUdThJU2JYK0piM3dadmdnS3FcL2RORkN1R1JIVllcL1hUbW1LZk8xXC9naER5RFZUWnIyTlNQS1NnQUZXT2xrUXROc2hnPT0ifQ%3D%3D&mrkid=114702534 https://www.fiercepharma.com/manufacturing/astrazeneca-unveils-massive-750m-deal-effort-to-produce-billions-covid-19-shots?mkt_tok=eyJpIjoiWkRkbE9XUTFNelEyTVdSaCIsInQiOiJvV050RVwveERldVVoZFVBaWt6VitmZ3lvVTNMUE1BQk9kbHpCRlVtaWhFK3FQSWhNRkM1XC9xbmliWmMwZTh5Mkh5OGJZSFNnNzhiSHRwYVlCTW1oU1RsRlROYWQwOEVSQWlWUzFuSWZZdDVsdUZodTJCQVViME5wZEp3RlV3S0lJUUQ2cHhhWXNDcDR1RnlRcnNKT3Fpdz09In0%3D&mrkid=114702534 https://endpts.com/astrazeneca-oxford-researchers-champion-a-one-two-punch-against-covid-19-in-first-human-study/ | |||||||||||||||||||||||||||
4 | 16/03/2020 | Vaccine | Ad5-nCov | CanSino and Beijing Inst. Tech | Mar 2020 | Recombinant vaccine candidate that entered Phase I in mid March and as of 14th April has started recruiting Phase II. Announced a partnership with Precision NanoSystems to start exploring an mRNA liquid nanoparticle vaccine. | Entered Phase I trials in March 2020 and Phase II in April 2020. Published data from Phase I trial in the Lancet on the 22nd May 2020 demonstrating a neutralising antibody and T cell response. "ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination." 6-17% of participants (depending on dose) suffered Grade 3 adverse events but no severe adverse events were reported. As of early June it was reported the Phase III trial was being planned in Brazil where the incidence levels are high. On 20th July data was published in the Lancet showing promising results - the vaccine drove a neutralising antibody response. | TBD | https://www.channelnewsasia.com/news/asia/covid-19-coronavirus-china-vaccine-clinical-trial-12565178 https://www.fiercepharma.com/vaccines/china-s-cansino-bio-advances-covid-19-vaccine-into-phase-2-preliminary-safety-data https://www.fiercebiotech.com/biotech/cansino-adds-mrna-to-covid-19-vaccine-efforts-precision-nanosystems-deal https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext | |||||||||||||||||||||||||||
5 | 27/04/2020 | Vaccine | BBIBP-CorV | Wuhan Institute of Biological Products & Sinopharm | Apr 2020 | Inactivated viral vaccine | Phase I underway. Published promising animal data in Cell on 16th June in mice and monkeys. Published Phase I and Phase II data in August. Shows that the virus drives antibodies but limited control data. | TBD | https://www.clinicaltrialsarena.com/news/china-third-covid-19-vaccine-trial/ https://www.fiercebiotech.com/research/inactivated-covid-19-vaccine-by-china-s-sinopharm-clears-animal-tests?mkt_tok=eyJpIjoiWVRGa01tTTVNMll6TURRNCIsInQiOiJISlM0WGJCYWFUVkdnOExcL3l5VXg3U1BGWTRiRzhHWlVkeStVemxmVm5LeStRSnRwQlVGcHZVekF3bzlFQ21KbW5pS2RDaFhsWlhWMDh6Z08rREZ4eHFNY25SbnFrR3c1eUIrNDQzeHd1Y05vMm1SKzZXRVZwdFJtc0JHcFRDbE9zUXRlR2hweXV1THpUclloVXNhbElnPT0ifQ%3D%3D&mrkid=114702534 https://www.fiercebiotech.com/biotech/sinopharm-shares-phase-2-data-inactivated-covid-19-vaccine?mkt_tok=eyJpIjoiTXpOaE56ZzBNR1F4TldGaiIsInQiOiJNZmdsM2k3dXNLaFdQZUt6VmhDc2hpMDU4K0lFb3VzdlBvTWk2Z2w1cENBK042Z2hEYW4ySUhHeEZ4ZUFQYXZRNmpyeTRLZkppQ2pWWUwzK3orSHU3ZTBBZnpWM3BRRStyMm9qMG5nK3ZxSncrcElsMHJWODl6UFVpUUViSHZpZE5LemJWYjhlMnJFT2gzVFdhdVA4dlE9PSJ9&mrkid=114702534 | |||||||||||||||||||||||||||
6 | 06/04/2020 | Vaccine | INO-4800 | Inovio | April 2020 | DNA plasmid containing the S protein delivered by electroporation | Phase I trial started 6th April 2020. Reported pre-clinical data in late May demonstrating a T cell response and neutralisign B cell response in mice and guinea pigs. The U.S. Department of Defense (DOD) inked a $71 million supply deal with the Pennsylvania biotech to manufacture devices that use electrical pulses to deliver the company’s vaccines into the skin. | $9M from CEPI | http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIOs-COVID-19-DNA-Vaccine-INO-4800-Demonstrates-Robust-Neutralizing-Antibody-and-T-Cell-Immune-Responses-in-Preclinical-Models/default.aspx https://www.fiercepharma.com/pharma/inovio-scores-71m-department-defense-deal-to-scale-up-vaccine-delivery-devices | |||||||||||||||||||||||||||
7 | 17/04/2020 | Vaccine | TBD | SinoVac | April 2020 | Inactivated virus | Phase I started 17th April 2020. Pre-print released on 23rd April that demonstrated vaccine had some efficacy in monkeys - at the time the first pre-print to provide efficacy data in non human primates. | http://www.sinovac.com/?optionid=754&auto_id=897, https://www.sciencemag.org/news/2020/04/covid-19-vaccine-protects-monkeys-new-coronavirus-chinese-biotech-reports | ||||||||||||||||||||||||||||
8 | Feb 2020 | Vaccine | LV-SMENP-DC | Shenzhen Geno Immune Medical Institute | April 2020 | DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs. Note this is not included on the WHO registered list. | Phase I trial started | https://clinicaltrials.gov/ct2/show/NCT04276896, https://www.nature.com/articles/d41573-020-00073-5 | ||||||||||||||||||||||||||||
9 | Feb 2020 | Vaccine | Pathogen Specific aAPC | Shenzhen Geno Immune Medical Institute | April 2020 | aAPCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins. Note - this is not included on the WHO registered list. | Phase I trial started | https://www.nature.com/articles/d41573-020-00073-5 | ||||||||||||||||||||||||||||
10 | 23/6/2020 | Vaccine | TBD | Institute of Medical Biology at Chinese Academy of Medical Sciences (IMBCAMS) | May 2020 | Inactivated viral vaccine | Phase I trial started in May and Phase II trial started in June. Limited data reported | https://www.reuters.com/article/us-health-coronavirus-china-vaccine/chinese-researchers-launch-phase-2-human-test-for-possible-coronavirus-vaccine-idUSKBN23S08H?il=0 | ||||||||||||||||||||||||||||
11 | 18/06/2020 | Vaccine | CVnCov | CureVac | June 2020 | mRNA vaccine. Received $213M in IPO in early August to support the vaccine programme, on the back of a $640M private round. | Received regulatory approval to start a Phase I trial on the 18th June | 300M EUR investment from German Government. Announced $640M private investment on 22nd July | https://www.fiercebiotech.com/biotech/curevac-gets-ok-to-start-testing-mrna-covid-19-vaccine-humans?mkt_tok=eyJpIjoiWVdSak5EWTFNMkV6TjJJeiIsInQiOiJOTWhiaTNmeE50OEw0UFwvSUkxeTl0alZqNUhJNEt6eTQ3YzBKd1RVMVcxN0ZkTGpIb3l4V1wvcFVacTBcL21hc3R0MmVMcjQ3SU44QlNkMXJjbnk4cFFjZDRVSGMyOHVxaVcxYTY3MmU0bUhubzlUN2dHem5sQ0Ftd1dJSGJiOVVSb2t6RlRRV0hSenpydCtaU2VcL3luWjlBPT0ifQ%3D%3D&mrkid=114702534 https://www.fiercebiotech.com/biotech/curevac-closes-640m-investment-amid-covid-19-vaccine-race?mkt_tok=eyJpIjoiWlRaalpEZzNaRE0yWTJVNCIsInQiOiJVQTR5QVBpTmNweExGZUVaQW14UEUzZ1lSMkl0OUdQRVRPWlZqV2trYzdJR1hENHUwUGxuMmxvd0g2YWFnYmVhWEVcLzNjWFk5bm81Zk14ckRsOHljY3pNYW5kOXdMdENSM3pzZ3lhb3ByXC9wWFBhejhSZTJ2bXBjSytJXC9PeFVIWmREcmdYR2hSa0cxZ1JsYThXdHdQb2c9PSJ9&mrkid=114702534 https://www.fiercebiotech.com/biotech/curevac-banks-213m-ipo-to-push-covid-19-vaccine-boost-manufacturing | |||||||||||||||||||||||||||
12 | 17/03/2020 | Vaccine | BNT162 | Pfizer and BioNTech | April 2020 | mRNA based vaccine candidates supplied by BioNTech and Pfizer will contribute global vaccine clinical research and development, regulatory, manufacturing and distribution infrastructure and capabilities. The U.S. clinical trial is studying four variants of the vaccine, code-named a1, b1, b2 and c2, to determine which combination of mRNA format and target antigen holds the most promise - variants include uridine-containing mRNA, nucleoside-modified mRNA or self-amplifying mRNA. | Have received regulatory approval to begin Phase I trial. On 29th April reports that first patients in a combined Phase I / II have been dosed in Germany. CEO also indicated promising data from rodents. As of 5th May 2020 first patients had been dosed in the US. Dose escalation trial is recruiting 360 patients out of New York and Maryland. In a phase 1/2 trial, all participants who received 10 micrograms (mcg) or 30 mcg of the mRNA vaccine candidate generated antibodies that were 1.8 times and 2.8 times higher, respectively, than the average of a group of patients who had confirmed prior infections. On 20th July announced that UK government has signed a deal for 90 million doses of the vaccine In late July the companies announced they had commenced a Phase III trial. | BioNTech receive $185 million (equity $113 million), milestone payments of up to $563 million As of 29th June a further $250M equity funding round was announced. | https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine https://www.fiercebiotech.com/biotech/pfizer-biontech-pfizer-finish-dosing-covid-19-vax-test-emergency-use-could-start-fall?mkt_tok=eyJpIjoiTnpreU1HUXhOV1EyTURkbCIsInQiOiIybkhYVHNFRjRZSlRqRFRpbFpcL3JFNG9GeG1KZFRia3oxTmVManF1VEphOHZ5NTZxSlpZUWhlZ3ZmMVFyaFNMNzRhU1NBM0FLOUlzeTZMN1VuN1BKMWRDejRQMVV6ZEwzVm1ueUs0VnBtTTR1YXBCQWZVR0QzZ0tXdytCXC9HUHBKYVhJNHVXK2gwbzcrZjBMV0JURW1EUT09In0%3D&mrkid=114702534 https://www.fiercebiotech.com/biotech/pfizer-biontech-dose-first-u-s-subject-covid-19-vaccine?mkt_tok=eyJpIjoiWmpReVpHRmhORFkwTjJKbCIsInQiOiJqVEY4Q0Y1SWdNeXRSUStHN0ZMVk0yT3ZIN01DV1M3WkFpOFwvcEQyWDRcL2JxSVhhZlc2T3Ezellsc3dZdDhTbEpOMkVaSngrQVwvTkFMWHd3VTU5akpaMTNaNlUzVzFZY3I1Y0ZNTWdSUFNZVHVFSmpyNllFTllaU2wzdWkxaHpaczUzZEVlR1wvc09Ta2dIRVBQdkZVREl3PT0ifQ%3D%3D&mrkid=114702534 https://www.fiercepharma.com/pharma/covid-19-vaccine-partners-pfizer-biontech-post-early-trial-win-eye-phase-3?mkt_tok=eyJpIjoiWTJFNFpHWmxNbUkwTW1NNCIsInQiOiJNRWdSYlpEalk1R3JRaTJ3OGtkejJ0Tmkyc2xTYmpzUlY3enZIek1ybjFseG5SRnhlejMzQTdrNkk2ODUzUHZ0NSs0R0pXYWxZNHUxaThoVWVtRmZcL21rUjh2XC9RTEUwQTJFZmtMNEtOS2Y1UlNkOGwyVXNBWVwveTdSUDJ2aThtcStyK3dlakhZS2Y1OVVLMkZBVHBESnc9PSJ9&mrkid=114702534 https://www.fiercebiotech.com/biotech/pfizer-biontech-start-their-covid-vax-phase-3-squaring-off-moderna?mkt_tok=eyJpIjoiWldabFlURTJZekV4WldSayIsInQiOiJyT2E3cGwrdTl6VEdUXC9OZlVFczMyV1B5ZElcL3ZYMWJVQnhFRlZhRWdLcVo0akRORWJTTWNCTlZ2dXNZRXY1K1pFNE1JXC9aaWlIS2xIa3JnWUdBK0VJek9FQ0V1VUdSY2cxeWt6WFRHMytmQllBZ0lnVGZPcENqUHNCREtVSDBNOWlXTWxQajRSUjBUQWdabGVDNnZ5SEE9PSJ9&mrkid=114702534 | |||||||||||||||||||||||||||
13 | 10/04/2020 | Vaccine | NVX-CoV2373 | Novavax | May 2020 | Pure spike nanoparticles. Received $200M investment from RA capital. | Trial begun in late May. Promising Phase III data from Flu. Early results, from the phase 1 part of a phase 1/2 study, show that two dose levels of the recombinant vaccine triggered an immune response similar to those in patients who had recovered from the disease (published in early August). | Up to $388M from CEPI $200M investment from RA Capital announced $1.6BN from US government as part of Warp speed | http://www.pmlive.com/pharma_news/novavax_fast-tracks_phase_1_testing_of_coronavirus_vaccine_1338039 https://www.globenewswire.com/news-release/2020/06/15/2048193/0/en/Novavax-to-Raise-200-Million-from-Private-Placement-with-RA-Capital.html https://www.fiercebiotech.com/biotech/novavax-s-covid-19-vaccine-looks-promising-early-data?mkt_tok=eyJpIjoiTlRsa1pXUXhORE15T0RFMSIsInQiOiJcLzkwM29jTmlHeGFBRGhtdFlRN0lxVWlpN21Sek1IWFhTWk5ua2NCcWlYbzlZN2IxU0FIYnVDYlVOamdcL0pVVHRQUkhXcFlQdjF0MHN5XC9iV0hMUUdSeDBjNDdQRlZvXC84TUM5cWJuSDQ2ZVdZV0Z3a0k1Qkl5ZSswM2tHQ2ExRm9CWlgwTGpiYlJvVHFQZmFUMlFuVzZ3PT0ifQ%3D%3D&mrkid=114702534 | |||||||||||||||||||||||||||
14 | 12/06/2020 | Vaccine | TBD | VacEquity Global Health (VGH) and Imperial | 15th June 2020 | Self amplifying RNA technology to generate the spike protein, based on the work of Professor Robin Shattock from Imperial College. | As of 24th June it was announced the first patients had been dosed in a Phase I trial. | UK Government Funding of £18.5M. Morningside and Imperial Ventures investment to start a social enterprise | ||||||||||||||||||||||||||||
15 | 28/05/2020 | Vaccine | TBD | Novartis & Massachusetts Eye & Ear Hosptial & University of Pennsylvania | Late summer 2020 | Novartis have agree dto manufacture a gene therapy based vaccine being developed by Massachusetts Eye and Ear hospital through their gene therapy unit AveXis.x` | None yet. | |||||||||||||||||||||||||||||
16 | 30/03/2020 | Vaccine (boost) | BCG Vaccine | Various (Netherlands and Australia) | Mar 2020 | Researchers in the Netherlands and Australia are investigating whether the BCG vaccine, originally developed for TB, can provide an innate immune system "boost" that protects front line workers in the short term. Note this is not really a SARS-CoV2 vaccine - but a repurposed existing vaccine. It's unlikely to have a "gold standard" effect | Preliminary data showing countries without a BCG vaccination system have higher Covid-19 mortality (pre-publication, not peer reviewed). | TBD | https://www.bloomberg.com/news/articles/2020-03-30/century-old-vaccine-investigated-as-a-weapon-against-coronavirus https://www.medrxiv.org/content/10.1101/2020.03.24.20042937v1 | |||||||||||||||||||||||||||
17 | 26/05/2020 | Vaccine | TBD | Merck & IAVI | Late 2020 | Merck announced a collaboration with IAVI a nonprofit scientific research organization. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s Ebola Zaire virus vaccine, ERVEBO® (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for this effort. | Vaccine currently in pre-clincial development. Platform has been validated with Ebola vaccine. | TBD - BARDA are providing funding | https://investors.merck.com/news/press-release-details/2020/IAVI-and-Merck-Collaborate-to-Develop-Vaccine-Against-SARS-CoV-2/default.aspx | |||||||||||||||||||||||||||
18 | 26/05/2020 | Vaccine | TBD | Merck | TBD | Merck announced acquisition of Themis - a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications. | Themis platform uses a modified measles vaccine virus as a vector and can be engineered to express a wide range of antigens. The measles vector is designed to provide a vehicle to deliver antigens to the immune system capable of triggering a protective memory response. It has been incorporated into vaccine development programs against infectious diseases including SARS, Chikungunya, MERS, and Lassa fever. Originally developed at the Institut Pasteur, the technology platform was first licensed to Themis in 2010. Themis has demonstrated the potential of its versatile platform through the rapid and successful completion of Phase 2 and progress towards Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. | https://investors.merck.com/news/press-release-details/2020/Merck-to-Acquire-Themis/default.aspx | ||||||||||||||||||||||||||||
19 | 18/02/2020 | Vaccine | TBD | Sanofi And BARDA | Q4 2020 | Recombinant, protein-based vaccine against COVID-19 which leverages SNY’s prior work for a SARS vaccine | Phase I trial planned for Q4 2020. | https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00 | ||||||||||||||||||||||||||||
20 | 14/04/2020 | Vaccine | TBD | GSK and Sanofi | Second half of 2020 | The two companies will combine innovative technologies to develop an adjuvanted COVID-19 vaccine, which is expected to enter clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021. The company has committed to manufacture 1 billion doses in 2021. On 5th July it was reported that GSK were close to agreeing a £500M deal with the UK government to supply 60 million doses of the vaccine. | Human trials are due to start in September. | TBD | https://www.thetimes.co.uk/article/glaxosmithkline-in-deal-with-rival-sanofi-to-make-coronavirus-vaccine-on-huge-scale-ls7tswm9h | |||||||||||||||||||||||||||
21 | 24/02/2020 | Vaccine | SCB-2019 | GSK and Clover Pharmaceuticals | H2 2020 | The vaccine is based on Clover’s Trimer-Tag vaccine technology platform and comes from early deals with GSK and Dynavax. GSK have offered to supply their vaccine adjuvants to various biotechs developing Covid19 vaccines | The company said the first participants have been dosed in its first clinical test w/c/ 15th June, and it's set up to assess its COVID-19 S-Trimer subunit vaccine candidate (SCB-2019). Top-line safety and immunogenicity data are slated to be ready in two months. The study is being conducted in Perth, Australia. | N/A | https://www.gsk.com/en-gb/media/resource-centre/our-contribution-to-the-fight-against-2019-ncov/#video | |||||||||||||||||||||||||||
22 | 03/04/2020 | Vaccine | TBD | GSK and Xiamen Innovax | TBD | Innovax is developing a vaccine with Xiamen University and will use a GSK adjuvant (AS03). | TBD | https://www.fiercebiotech.com/biotech/gsk-allies-innovax-for-covid-19-vaccine-r-d-project?mkt_tok=eyJpIjoiTW1abVptTXhPRE5pTURNMSIsInQiOiJVMDZjK3NtckFLUEhNUEEyQXYrelg5U2RleGFzd0hpaEk1VlBrVDZ4Y3pXZDd0anpQRTh4WG5XU3djcnlYd0xYRzZsamRuMmIydEk0dnVVMjBsRlB3MExIcTRtUTRGV08xYitYS1BvUkltNW41enRPbXJLWGo4Z0haUWVJcVF3K0pNbUgyWERJSHlYQUR1YUY4RUN6aFE9PSJ9&mrkid=114702534 | ||||||||||||||||||||||||||||
23 | N/A | Vaccine | TBD | DIOSynVax | March 2021 | DNA based vaccine designed to reduce risk of ADE | 0 | |||||||||||||||||||||||||||||
24 | 25/03/2020 | Vaccine | TBD | eTheRNA | TBD | TriMax platform has experience in developing mRNA based vaccines by selecting conserved epitopes | None - collaboration recently launched to deliver vaccine, adjuvanta and intranasal spray | TBD | ||||||||||||||||||||||||||||
25 | 30/03/2020 | Vaccine | Ad26-SARS-CoV2 | Johnson & Johnson, in partnership with BARDA | September 2020 | "The J&J candidate (as well as two other backups) was created on an adenovirus vector-based platform in a collaboration between its Janssen unit and researchers at Harvard’s Beth Israel Deaconess Medical Center. They began working with multiple constructs back in January, the company added, selecting the ones producing the largest immune response in preclinical experiments. Initial safety and efficacy data are available by the end of the year." | In late July 2020 published data in Nature showing the vaccine was protective in non human primates. Trial has now commenced (Phase I) in Belgium and the US | $1BN committed from BARDA | https://endpts.com/covid-19-roundup-fda-authorizes-emergency-use-of-hydroxychloroquine-as-donations-from-novartis-bayer-flood-in/?utm_medium=email&utm_campaign=940%20Monday%20March%2030th%20-%20JJ%20launches%201B%20race%20to%20the%20finish%20line%20for%20Covid-19%20vaccine%20David%20Hallal%20boosts%20startups%20backing%20to%20320M&utm_content=940%20Monday%20March%2030th%20-%20JJ%20launches%201B%20race%20to%20the%20finish%20line%20for%20Covid-19%20vaccine%20David%20Hallal%20boosts%20startups%20backing%20to%20320M+CID_e3d317c97ea49d538c0f3ead8739968e&utm_source=ENDPOINTS%20emails&utm_term=Covid-19%20roundup%20JJ%20BARDA%20set%20early%202021%20finish%20line%20for%201B%20vaccine%20race%20FDA%20allows%20emergency%20Covid-19%20drug%20use%20ahead%20of%20pivotal%20data https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use https://www.jpost.com/breaking-news/johnson-and-johnson-to-start-coronavirus-vaccine-human-trials-in-september-622934 https://www.nature.com/articles/s41586-020-2607-z | |||||||||||||||||||||||||||
26 | 03/04/2020 | Vaccine | TBD | University of Pittsburgh | TBD | Microneedle patch that delivers vaccine into the skin. Shows efficacy in mice. Team developed a similar patch against MERS that generated antibodies that lasted for 1 year. | Device generated antibodies in mice after two weeks - see publication reference. | TBD | https://www.thelancet.com/pdfs/journals/ebiom/PIIS2352-3964(20)30118-3.pdf | |||||||||||||||||||||||||||
27 | 08/04/2020 | Vaccine | TBD | University of Georgia | TBD | Team are developing a vaccine that delivers the SARS spike protein within the canine respiratory virus PIV5 that causes kennel cough in dogs, but not does not cause disease in humans | Mouse data indicated approach could provide immunity to MERS. Team currently working on PIV5 that expresses SARS-CoV2 spike protein | TBD | https://www.fiercebiotech.com/research/turning-virus-causes-kennel-cough-dogs-against-covid-19 | |||||||||||||||||||||||||||
28 | 16/04/2020 | Vaccine | TBD | Dynavax and Sinovac | TBD | Dynavax and Sinovac are teaming up on a vaccine for COVID-19, combining the former’s vaccine adjuvant with the latter’s chemically inactivated coronavirus vaccine candidate. | TBD | https://www.fiercebiotech.com/biotech/dynavax-sinovac-latest-to-ally-a-covid-19-vaccine?mkt_tok=eyJpIjoiT0RsalpESmtZems1WldWayIsInQiOiJyU1dKbmQyWjlVdE1PSFgra1lUblNRTWVnenZZZjdMY3lEMnE1a2tpaGZOdW5qQ0hHVzBDS1BLMHVHZXVQTXFVWDEybDNQaWhweUpsUkRvMkRnek1ZRklPVjZZend5eHBOaDh5ZXJZam5wdWJFaGdcL2RRcVI0cFwvWDNxNGRiN20wQndTS0RFOXhpXC9ZZnlZTWlScFhTNVE9PSJ9&mrkid=114702534 | / | / | ||||||||||||||||||||||||||
29 | 25/02/2020 | Antiviral | Remdesivir | Gilead | Mar 2020 | Broad antiviral has been named as a WHO priority. Monophosphate prodrug that undergoes metabolism to an active C-adenosine nucleoside triphosphate analogue that inhibits RNA polymerase. Previously showed promise with MERS. Being included in WHO coordinated trial (SOLIDARITY) At least 6 clinical trials ongoing. Reported in late June that Gilead are planning on trialing delivering the drug in inhaled form so that it can be used earlier in patients - approved drug requires intravenous injection and therefore often only delivered late on in disease progression. | Ph II clinical trial in US, c. 400 patients, ongoing. 1 patient treated in the US with positive findings (n=1 so very preliminary). Gilead provided results from 53 severe COVID-19 patients treated with remdesivir on a compassionate use basis in a paper published in The New England Journal of Medicine on 12th April. During a median follow-up of 18 days, 36 patients (68%) had a clinical improvement, and the mortality rate was 18% among patients receiving invasive ventilation. Jefferies analysts argue the data "suggest remdesivir may work and is generally safe. However there was no control arm in the study. Later reports from the University of Chicago were also promising. However a RCT trial from China (which was stopped early due to patient shortage) was reported as a "flop." Analysts indicate that the drug may have to be administered early for there to be an impacta and the Chinese study allowed administration up to 12 days after symptom onset. As of 29th April the company was reporting that a trial on moderate and severe patients "had met its primary endpoint" causing Gilead's share price to surge. | TBD | https://www.nejm.org/doi/full/10.1056/NEJMoa2001191, https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments; https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials https://www.fiercepharma.com/pharma/coronavirus-outbreak-climbs-to-more-than-6-000-cases-track-pharma-response-here?mkt_tok=eyJpIjoiWWpJMVptRTRZMlExTldWaSIsInQiOiJXS1lzck1oQStmakI0VDdsbFpkZXd2MkxSck9wUDkzZXBVbjdyZDRyWkRVaDVybUQyZFVxZHpHS0FDS2F6Q2FEVG9yRFNpbWdpbGpjOGdOa2dOb0ZyXC91emJBeUZsNmR4dzdwamx6XC8rZGdXaDFCbkNcL1luZWkzdUUwQTE1ZDBjRWp5SERCSkNyalMrQ1hNVmFWTVo4THc9PSJ9&mrkid=114702534 https://www.nejm.org/doi/full/10.1056/NEJMoa2007016?query=featured_coronavirus https://www.fiercebiotech.com/biotech/gilead-remdesivir-data-likely-enough-for-speedy-fda-approval-jefferies?mkt_tok=eyJpIjoiTnpreU1HUXhOV1EyTURkbCIsInQiOiIybkhYVHNFRjRZSlRqRFRpbFpcL3JFNG9GeG1KZFRia3oxTmVManF1VEphOHZ5NTZxSlpZUWhlZ3ZmMVFyaFNMNzRhU1NBM0FLOUlzeTZMN1VuN1BKMWRDejRQMVV6ZEwzVm1ueUs0VnBtTTR1YXBCQWZVR0QzZ0tXdytCXC9HUHBKYVhJNHVXK2gwbzcrZjBMV0JURW1EUT09In0%3D&mrkid=114702534 https://endpts.com/hydroxychloroquine-studies-grind-to-a-halt-as-trumps-frequently-touted-favorite-sputters-into-the-futility-zone/ | |||||||||||||||||||||||||||
30 | 09/05/2020 | Antiviral | Interferon beta-1b, lopinavir-ritonavir, and ribavirin | Various | Mar 2020 | Phase II trial of "triple antiviral" therapy on 86 patients, reduced mean hospital stay from 14 days to 9, and reduced viral load in mild / moderate patients. | Publication in the Lancet. Requires Phase III trial to fully investigate / confirm findings. | TBD | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext?utm_campaign=tlcoronavirus20&utm_content=128971480&utm_medium=social&utm_source=twitter&hss_channel=tw-27013292 | |||||||||||||||||||||||||||
31 | 20/03/20 | Antiviral | Chloroquine, Hydroxychloroquine | AbbVie, Ascletis (generic), Novartis | Mar 2020 | Anti-malarial that is also a Zinc Ionophore. Thought to prevent ORF1/2 attacking haem. Novartis agreed to provide 130 million doses free. Received emergency FDA approval on 30th March allowing US hospitals to start prescribing the stockpiles that have been donated by pharma companies (pre clinical trials results) | *** as of 26th May the WHO announced pausing all trials into hydroxychloroquie and chloroquine due to adverse cardiac effects. An analysis of 3,700 patients published in the Lancet found patients treated with the drugs were assocaited with increased mortality*** Included in a WHO coordinated trial (SOLIDARITY). Multiple studies indicating cautious with potential limited efficacy and serious side effects. E.g. a French study reported 43 heart incidents tied to hydroxychloroquine. As of 8th June the UK reported the preliminary results of their trial and also reported no impact. | TBD | https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173 https://www.businessinsider.com/study-results-chloroquine-hydroxychloroquine-as-covid-19-treatment-2020-4?r=US&IR=T https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext https://www.ukri.org/news/preliminary-results-from-recovery-trial-on-the-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19/ | |||||||||||||||||||||||||||
32 | 26/05/2020 | Antiviral | EIDD-2801 | Merck and Ridgeback Bio | TBD - Phase I data has shown it to be well tolerated | EIDD-2801 is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University. | In animal studies of two distinct coronaviruses (SARS-CoV-1 and MERS), EIDD-2801 has been shown to improve pulmonary function, decrease body-weight loss and reduce the amount of virus in the lung. Company reported moving to Phase II trials after promising Phase I data in late June. | TBD | https://investors.merck.com/news/press-release-details/2020/Merck-and-Ridgeback-Bio-Collaborate-to-Advance-Development-of-Novel-Antiviral-Candidate-EIDD-2801/default.aspx https://endpts.com/hydroxychloroquine-studies-grind-to-a-halt-as-trumps-frequently-touted-favorite-sputters-into-the-futility-zone/ | |||||||||||||||||||||||||||
33 | 18/03/2020 | Antiviral | Favipiravir / Avigan | Fujifilm Tomoya Chemical | Feb 2020 | Favipiravir, previously known as T-705, is a prodrug of a purine nucleotide, favipiravir ribofuranosyl-5′-triphosphate. The active agent inhibits the RNA polymerase, halting viral replication. | Chinese trials on 340 patients showed reduction in testing positive from 11 days to 4 and 91% patients showed improvements in lung conditions. Most of favipiravir preclinical data are derived from its influenza and Ebola activity; however, the agent also demonstrated broad activity against other RNA viruses. In vitro, the EC50 of favipiravir against SARS-CoV-2 was 61.88 μM/L in Vero E6 cells. Started a Phase II Trial in April 2020. | TBD | https://techcrunch.com/2020/03/18/japanese-flu-drug-appears-effective-in-coronavirus-treatment-in-chinese-clinical-trials/ https://jamanetwork.com/journals/jama/fullarticle/2764727 | |||||||||||||||||||||||||||
34 | 24/03/2020 | Antiviral | Arbidol / Umifenovir | Pharmstandard | February 2020 | Broad antiviral. Targets S protein/ACE2 interaction and inhibiting membrane fusion of the viral envelope. | Early data indicates no efficacy, Supported by a Chinese study. | https://www.fiercepharma.com/pharma-asia/top-covid-19-aspirants-chloroquine-abbvie-s-kaletra-and-a-flu-drug-disappoint-clinical | ||||||||||||||||||||||||||||
35 | 23/03/2020 | Antiviral | Lopinavir/ritonavir alone or with interferons (Kaletra) | AbbVie | April 2020 | Anti HIV drugs - retroviral | Used in South Korea and Singapore. NEJM paper with c. 200 patients observed no difference in outcome. However, was administered up to two weeks after the onset of symptoms and needs to be given in first couple of day. UK Government have announced funding for clinical trial in the UK and also being included in the WHO coordinated SOLIDARITY trial | £2.1M | https://www.nejm.org/doi/full/10.1056/NEJMoa2001282 | |||||||||||||||||||||||||||
36 | 16/03/2020 | Anti-viral | Oseltamivir (Tamiflu) | Roche | TBD | Antiviral used previously in Swine Flu epidemic | Administered in Singapore, no efficacy data. Data from Iran says not effective | TBD | https://ifpnews.com/tamiflu-not-effective-in-treating-covid-19-iran | |||||||||||||||||||||||||||
37 | 05/03/2020 | Antiviral | Camostat Mesylate / Foipan | TBD | TBD | Infection relies on ACE2 and TMPRSS2, which can be blocked by approved protease inhibitor Camostat Mesylate. In vitro research published in Cell demonstrates potential efficacy | No robust human data yet | TBD | https://linkinghub.elsevier.com/retrieve/pii/S0092867420302294, https://link.springer.com/article/10.1007%2Fs00134-020-05985-9 | |||||||||||||||||||||||||||
38 | 18/03/2020 | Antiviral | Prezcobix / Darunavir | Janssen, J&J | Feb 2020 | HIV Protease inhibitor drug | Early didn't indicated no efficacy | N/A | https://www.biospace.com/article/j-and-j-says-hiv-drug-darunavir-hasn-t-been-proven-to-be-effective-for-covid-19-treatment/ | |||||||||||||||||||||||||||
39 | 27/02/2020 | Antiviral | Baricitinib / Olumiant | Eli Lilly, Benevolent AI | May 2020 | Benevolent AI identified in silico as a promising drug candidate that may inhibit the virus. Also functions as a JAK inhibitor which may suppress the cytokine storm. Eli Lilly announced in April a plan to test the drug in the drug in clinical trials following pre-clinical evaluation. Also known as LY3127804? | Limited - identified in silico and no human data yet. Phase III trial had started as of 16th June. | N/A | https://linkinghub.elsevier.com/retrieve/pii/S1473309920301328, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30132-8/fulltext, https://www.fiercepharma.com/pharma/lilly-partners-nih-to-test-olumiant-patients-hospitalized-covid-19?mkt_tok=eyJpIjoiWWpJMVptRTRZMlExTldWaSIsInQiOiJXS1lzck1oQStmakI0VDdsbFpkZXd2MkxSck9wUDkzZXBVbjdyZDRyWkRVaDVybUQyZFVxZHpHS0FDS2F6Q2FEVG9yRFNpbWdpbGpjOGdOa2dOb0ZyXC91emJBeUZsNmR4dzdwamx6XC8rZGdXaDFCbkNcL1luZWkzdUUwQTE1ZDBjRWp5SERCSkNyalMrQ1hNVmFWTVo4THc9PSJ9&mrkid=114702534 https://www.fiercepharma.com/pharma/lilly-starts-testing-arthritis-med-olumiant-covid-19-alongside-antibody-works?mkt_tok=eyJpIjoiTnpOaE5HWmpORGd5TlRrMyIsInQiOiJwWnNsczIyRkNKSms5eWo2XC8xVTI4cWcrUEZtNGU0OHlOM3VNbVZnMHBrQ2JlXC9tVm16aER4eFZsVElLZ3M1M0lSV00xOWRtRExFcFVrODkxWnlLTlBUdVhSTXFkMnpsOHlXeWsxTmNJSlY2Vk85anBlMGc2SEFSb2dKOUgyOEJubG5tSXlSWEJYUkcrWk5Qd0k2Q0RQdz09In0%3D&mrkid=114702534 | |||||||||||||||||||||||||||
40 | 23/03/2020 | Antiviral | TBD | Queen's University Belfast | N/A | Screening 1000 approved drugs to see if they can be repurposed against Coronavirus | None yet | £0.3M | https://mrc.ukri.org/news/browse/covid-19-vaccine-therapy-research-boosted-by-six-new-projects-in-rapid-response/?utm_medium=email&utm_source=govdelivery | |||||||||||||||||||||||||||
41 | 02/04/2020 | Antiviral | APN01 | Apeiron Biologics | TBD | APN01 is the recombinant version of the human angiotensin-converting enzyme 2 (rhACE2) with a dual mechanism of action. | Regulatory approval granted in early April for a Phase II trial. | https://www.clinicaltrialsarena.com/news/apeiron-biologics-phaseii-covid-19/ | ||||||||||||||||||||||||||||
42 | 03/04/2020 | Antiviral | VIR-2703 and ALN-COV | Vir and Alnylam | Q4 2020 | Developing RNAi therapeutics that target three targets for SARS CoV2 including ACE2 and TMPRSS2 | None yet | https://www.pharmaceutical-technology.com/news/vir-alnylam-expand-covid-19-deal/ https://www.fiercebiotech.com/biotech/alnylam-vir-plan-year-end-trial-new-rnai-covid-19-antiviral | ||||||||||||||||||||||||||||
43 | 27/04/2020 | Antiviral | NT-300 | Romark | April / May 2020 | In cell cultures, the active ingredient in NT-300, nitazoxanide, inhibits replication of a broad range of respiratory viruses, including the SARS-CoV-2 virus that causes COVID-19.1-4 Nitazoxanide has also been shown to inhibit replication of SARS, MERS and other coronaviruses as well as influenza viruses, rhinoviruses, parainfluenza viruses, RSV and other respiratory viruses in cell culture studies.2-4 The broad-spectrum antiviral activity of nitazoxanide is attributed to its interference with human cellular pathways that the virus exploits to replicate, rather than to a virus-targeted mechanism.2,4 | Phase III study with 300 elderly patients starting end of April 2020 | https://www.biospace.com/article/releases/romark-initiates-phase-3-clinical-trials-of-nt-300-for-covid-19/ | ||||||||||||||||||||||||||||
44 | 06/04/2020 | Antiviral | Truvada | TBD | April 2020 | Truvada is a combination of two drugs (Emtricitabine and tenofovir) that is used to prophylactically to prevent HIV infection. | Clinical trial started recruiting in April 2020 | https://clinicaltrials.gov/ct2/show/NCT04334928 | ||||||||||||||||||||||||||||
45 | 14/04/2020 | TBD | N-803 | Immunity Bio | TBD | Interleukin 15 (IL-15) ‘superagonist’ cytokine to stimulate natural killer cells and CD8+ T cells | None yet | https://immunitybio.com/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/ | ||||||||||||||||||||||||||||
46 | 05/06/2020 | Antibody Therapy (Anti-Viral) | 47D11 | AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center | TBD | Collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus. The focus of the collaboration is on advancing the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM and recently reported in Nature Communications. This antibody targets the conserved domain of the spike protein of SARS-CoV-2. | Antibody was published in Nature Communications with IC50 values of 0.061 and 0.061 μg/ml (https://www.nature.com/articles/s41467-020-16256-y) | TBD | https://news.abbvie.com/news/press-releases/abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-to-develop-monoclonal-antibody-therapy-to-prevent-and-treat-covid-19.htm?view_id=362 | |||||||||||||||||||||||||||
47 | 04/03/2020 | Antibody Therapy (Anti-Viral) | Tak-888 (Convalescent Plasma) | Takeda, CSL Behrin, | Transferring plasma from recovered patients to those currently fighting the disease with the idea that neutralising antibodies will aid the fight against the virus. Teamed up to form the CoVIg-19 Plasma Alliance to accelerate convalescent plasma treatment in the US, along with Biotest, BPL, LFB, OctaPharma, CSL, Behring and Takeda. | Used on trial basis in China (3 of 5 patients discharged from the hospital and 2 stable),. As of 7th May trial had begun in the UK using this approach. FDA approved convalescent plasma for very sick patients.The method has been used in the past to treat diseases such as polio, measles, and mumps, in the 1918 flu epidemic, and in previous outbreaks of respiratory infections similar to covid-19. | N/A | https://www.channelnewsasia.com/news/asia/chinese-doctors-using-plasma-therapy-on-covid-19-patients-12444244, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30141-9/fulltext, https://www.takeda.com/newsroom/newsreleases/2020/takeda-initiates-development-of-a-plasma-derived-therapy-for-covid-19/ https://www.covig-19plasmaalliance.org/en-us#recruitment https://www.fiercebiotech.com/biotech/takeda-csl-led-alliance-and-nih-to-test-plasma-treatment-summer | ||||||||||||||||||||||||||||
48 | 06/05/2020 | Antibody Therapy (Anti-Viral) | Convalescent Plasma | CSL | TBD | Convalescent plasma therapy - CSL expects around 800 plasma donations will be needed to produce enough immunoglobulin to treat around 50-100 seriously ill people under the clinical trial, it said. | None yet. | https://uk.reuters.com/article/health-coronavirus-csl/australias-csl-to-start-work-on-immunoglobulin-product-to-treat-covid-19-idUKL4N2CO00N | ||||||||||||||||||||||||||||
49 | 24/03/2020 | Antibody Therapy (Anti-Viral) | Convalescent Plasma | Mayo Clinic & Amazon, Grifols supporting plasma collection | April 2020 | Mayo clinic is coordinating an effort across 20 institutions in the US to share convalescent plasma. Amazon are said to be building a website to accommodate distribution and coordination. | Used on trial basis in China but no data reported. FDA approved convalescent plasma for very sick patients.The method has been used in the past to treat diseases such as polio, measles, and mumps, in the 1918 flu epidemic, and in previous outbreaks of respiratory infections similar to covid-19. | https://www.bmj.com/content/368/bmj.m1256, https://www.businessinsider.com/coronavirus-convalescent-plasma-treatment-early-chinese-study-results-2020-3?r=US&IR=T | ||||||||||||||||||||||||||||
50 | 23/03/2020 | Antibody Therapy (Anti-Viral) | TBD | Chelsea & Westminster, Imperial | TBD | In collaboration with China team are developing neutralising antibodies | £0.6M | https://mrc.ukri.org/news/browse/covid-19-vaccine-therapy-research-boosted-by-six-new-projects-in-rapid-response/?utm_medium=email&utm_source=govdelivery | ||||||||||||||||||||||||||||
51 | 16/03/2020 | Antibody Therapy (Anti-Viral) | LY-CoV555 | Eli Lilly and AbCellera | July 2020 | 500 human antibody sequences identified and being tested for therapeutic potential. As of 1st June it was announced that a Phase I clinical trial had begun. | Reported that trials were starting at the NIH using the antibody candidate in July. | $175.6M received in grant funding from Canadian government | https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/ https://www.fiercebiotech.com/biotech/lilly-partnered-abcellera-gets-covid-19-boost-from-canadian-government https://www.fiercebiotech.com/biotech/lilly-starts-first-clinical-trial-covid-19-antibody-therapy https://www.fiercebiotech.com/biotech/nih-to-test-covid-19-antibodies-hospitalized-patients-starting-eli-lilly-s?mkt_tok=eyJpIjoiTlRsa1pXUXhORE15T0RFMSIsInQiOiJcLzkwM29jTmlHeGFBRGhtdFlRN0lxVWlpN21Sek1IWFhTWk5ua2NCcWlYbzlZN2IxU0FIYnVDYlVOamdcL0pVVHRQUkhXcFlQdjF0MHN5XC9iV0hMUUdSeDBjNDdQRlZvXC84TUM5cWJuSDQ2ZVdZV0Z3a0k1Qkl5ZSswM2tHQ2ExRm9CWlgwTGpiYlJvVHFQZmFUMlFuVzZ3PT0ifQ%3D%3D&mrkid=114702534 | |||||||||||||||||||||||||||
52 | 07/05/2020 | Antibody Therapy (Anti-Viral) | JS016 | Eli LIlly and Junshi Biosciences | Phase I trials were reported to have started on teh 9th June 2020. | $10M upfront, up to $245M committed | https://www.fiercebiotech.com/research/battling-covid-19-neutralizing-antibodies https://www.fiercebiotech.com/biotech/lilly-starts-second-covid-19-antibody-test-partner-junshi-biosciences-eyes-combo-trials?mkt_tok=eyJpIjoiT0dZd05USTJaVEUxTjJaaCIsInQiOiJyUXFGSlJcL2Q1UmFOeTZGdEdoamV3Vzl0dDhRWEVvRGpoZ2ZQTDdOOTYwY3JYSHBUc3FIOGJINmo0UUE5V1UrcFd3dDFWRlp3U216aXIxRWpLY2FNNWJxK0EwRjJiOU1zWjVVeXcwdmlMTlh6ZElCYnhYbUN5SXBDemxxU2pzbzgrSnU0SUNFRVBwSFFqXC95dUdYUG91dz09In0%3D&mrkid=114702534 | |||||||||||||||||||||||||||||
53 | 11/05/2020 | Antibody Therapy (Anti-Viral) | COVI-SHIELD | Sorrento and Mount Sinai | Q3 2020 | Developing cocktail targetting multiple epitopes on the virus. Engineering antibodies so they have low risk of ADE. Partnering with Mount Sinai to leverage antibody expertise | Sorrento announced on the 15th May that they have identified an antibody candidate that was very effective at neutralising the virus in vitro studies and will likely form the first component of their cocktail. | TBD | https://www.fiercebiotech.com/research/sorrento-ventures-into-covid-19-mount-sinai-antibody-pact?mkt_tok=eyJpIjoiTkRNNU1UTXhORFZpTmpjeiIsInQiOiI2TXRDSFJSVlZZSlg3Sm1ZbmxTRGxBME16dUJjOXl3dm8ydFpYYWFsVG9XK051ak5cL1IzXC92RzBwa3o1XC9QYXhob3JldWc4RkE4RzNCSjJleFNnblRTbGpZMm9xSGlpcWVFdDdQcFFUdDhWTEVsN1Vld0xnQmZFWU9vMkZoYVg2bUkzdkY4UUdoTHVxaE9TUVBwSFFzMUE9PSJ9&mrkid=114702534 https://techcrunch.com/2020/05/15/sorrento-finds-a-coronavirus-antibody-that-blocks-viral-infection-100-in-preclinical-lab-experiments/ | |||||||||||||||||||||||||||
54 | 30/03/2020 | Antibody Therapy (Anti Viral) | rCIG (recombinant anti coronavirus 19 hyperimmune gamma globulin) | GigaGen | Single cell sequencing of convalescent B cell repertoire in order to select which antibodies to produce | None yet - small start up | TBD | https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies | ||||||||||||||||||||||||||||
55 | 17/03/2020 | Antibody Therapy (Anti-Viral) | REGN-Cov2 | Regeneron | June / July 2020 | Mixed antibody therapy with human clinical trial planned for the summer | Regeneron are identifying a cocktail of antibodies based on mouse studies that may neutralise the virus. As of the 11th June 2020 it was reported that testing in humans had begun. They reported pre-clinical findings in Science showing that the two antibodies they selected; REGN10933 and REGN10987 bind to non-overlapping regions of the target protein, which “may provide enhanced protection against loss of efficacy,” they wrote in the study. Entered the clinic on the 11th June for therapeutic, and 6th July for prophylactic. | N/A | https://www.nasdaq.com/articles/regeneron-could-start-a-covid-19-treatment-test-this-summer-2020-03-17 https://www.fiercebiotech.com/biotech/regeneron-starts-testing-covid-19-antibody-cocktail-humans?mkt_tok=eyJpIjoiWVdFMFpEUXlOREJsTnpRNCIsInQiOiJJT3Jsd0h5Y3VvVk5VZnpFNjU3S0EwUXFZREYwY28zaFwvV1FFRmtHbGF4NXg5eUUyeHMwZUU5eUxvNmlyTElxV0dOWEtER2QzUGhMdWMyQ3Q3ZkgzYlB1WmVGcFBKSmdEVnhRaHZ2Z1wvaTAyQURqYkZuWk1QNmxxdWZSSUhwNkxwOTRpaUx0WFQ1dU5iQVg3OUJPV2pzUT09In0%3D&mrkid=114702534 https://www.fiercebiotech.com/research/how-regeneron-s-covid-19-antibody-cocktail-cuts-risk-resistance?mkt_tok=eyJpIjoiWXpKa1kyRTROR0UxTVRNeCIsInQiOiJvY01oT2pRNHJidlk0SVZzWmxDTjd6bFJoSDB6SWVHNFwvbUg5ZFQzRzREekFrcUFTUmxlOFVwaUVnZlNjR3BuNlQwM1ZRaURHdkorRGtEdmY1ZkVjcjFVNDhQMm5SMnRNSzg5cE1iTUsrKzhmQTdTZG95cktyVGpUMGpcL25CK1Y0K1pUVW93aDkrQnNvVFBhWTJReW92dz09In0%3D&mrkid=114702534 | |||||||||||||||||||||||||||
56 | 01/04/2020 | Antibody Therapy (Anti-Viral) | TBD | Brii | Q3 2020 | Tsinghua University and Shenzhen No.3 People’s Hospital isolated and characterized monoclonal antibodies specific to the viral spike protein receptor-binding domain, resulting in a pool of 206 prospects taken from eight individuals infected with the virus. Effort is focusing on two antibodies | In vitro data only (see pre-print document in reference) | https://www.fiercebiotech.com/biotech/brii-chinese-partners-eye-q3-start-for-covid-19-antibody-trial?mkt_tok=eyJpIjoiT0RZNE5UQTJOVEJtT0RZMCIsInQiOiJCbytTWXJoYUw3VFNhYndZZ2g1bm5VT3YxWW9HajViTGVOSEZHOWdvb0l1YUljWUltNTR4RnBVUXFycWt6R1p4UitmazB1OTdiNE1UckJWQnZDWHBRK2xCQTVFbGhMWDVvZEF3bWEwWitHYVNUUUJuZUY0QXJGSk5rbTN2eDdcL2ZZc2xIbEFlVlhZNE9qSEMrZklOOVRBPT0ifQ%3D%3D&mrkid=114702534 https://www.biorxiv.org/content/10.1101/2020.03.21.990770v2.full.pdf | ||||||||||||||||||||||||||||
57 | 02/04/2020 | Antibody Therapy (Anti-Viral) | TBD | Amgen and Adaptive Biotechnologies | TBD | Adaptive will screen the genetic diversity of the B cell receptors from individuals that have recovered from COVID-19 to select those that neutralize SARS-CoV-2. Amgen will to select, develop and manufacture antibodies designed to bind and neutralize SARS-CoV-2. deCODE Genetics, a subsidiary of Amgen will provide genetic insights from patients. | None yet | http://investors.amgen.com/news-releases/news-release-details/amgen-and-adaptive-biotechnologies-announce-strategic | ||||||||||||||||||||||||||||
58 | 06/04/2020 | Antibody Therapy (Anti-Viral) | VIR 7831 and VIR 7832 | VIR and GSK | July - Sep 2020 for Phase II | GSK have invested $250M in VIR who are developing two neutralising antibody candidates. | Phase II / III trial started at end of August 2020. | $250M from GSK | https://endpts.com/gsks-hal-barron-buys-a-250m-stake-in-george-scangos-vir-and-makes-a-bee-line-to-the-clinic-with-covid-19-antibodies/ https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/ | |||||||||||||||||||||||||||
59 | 08/04/2020 | Antibody Therapy (Anti-Viral) | AZD7442 | AstraZeneca | August 2020 | AstraZeneca tweeted that they are working closely with the UK government to identify monoclonal antibodies that can neutralise SARS-CoV 2. Working with three sources - convalescent patient plasma, humanised mice and phage display. The plan to enter the clinic between July and September. Licenced candidate from Vandebralt university in June | Phase I trial started 24th August 2020. Neutralisatio capacity published in Nature. | TBD | https://twitter.com/AstraZeneca/status/1247812712651845633 | |||||||||||||||||||||||||||
60 | 14/04/2020 | Antibody Therapy (Anti-Viral) | TBD | Cellitron | July 2020 | Cellitron (South Korean drug developer) have selected the most promising neutralising antibody candidates and is aiming to enter the clinic in July. | https://www.fiercebiotech.com/biotech/celltrion-plans-july-covid-19-trial-advances-super-antibody?mkt_tok=eyJpIjoiTm1ZNFpqWXhOMlpoTnpCayIsInQiOiJcLzgxcDRsOFdoUDFrZzZ2NGd5NSt6dUNqeGRxZWsxaFNYZHFaVkcyQ3RGUWpsRE45SWJvRlNPR2xmWFBTdGpaY3FOSzB3WWIxRjhrMVRLY1VFZ3JiTExqZkZaNkFYUFBka0FVVVRWN2RkUFZudlp3WVBvMVVRS2JDNVdqUU1PNm1QWHJMNytMM3plU1RpQTJJeGpaUDhnPT0ifQ%3D%3D&mrkid=114702534 | |||||||||||||||||||||||||||||
61 | 02/06/2020 | Symptoms: Biologics | TJM2 | I-MAB | Spring 2020 | TJM2 is an antibody that inhibits GM-CSF, a cytokine that’s known to contribute to tissue inflammation and degeneration in diseases such as rheumatoid arthritis (RA). | As of June 2020 a Phase I trial had been completed. In part one of I-MAB’s trial, 24 patients were randomized to receive one of two doses of TJM2 or a placebo. The company didn’t provide many details about the results except to note a “correlation between clinical improvement and reduced levels of some disease related cytokines.” The higher of the two doses of TJM2 will be tested against a placebo in the next phase of the study, which will include 120 patients. | https://www.fiercebiotech.com/research/i-mab-advances-repositioned-ra-drug-early-trial-to-treat-covid-19-cytokine-storm?mkt_tok=eyJpIjoiTXpVeU9XWm1ZVEpoWTJNNSIsInQiOiJCMVpNUmZ4cHNyNEpQV3RFb0d5NUZ5OWJmUHJWQmozTm9NVXRPdEpSREhxdlpNQ01ZNWRVZWxnRkJwcTdOMEZ1NXJjZXRyNk1TNXIxc3dKbW95YU9MZzF3NUQyU0tMaVZnc2x0bExweGxYZlVGMTNvT2R2VWR2MjZIWFcyZXNDXC9lZEZKK2h2RDZUVWZyRU9OREtOeDhRPT0ifQ%3D%3D&mrkid=114702534 | ||||||||||||||||||||||||||||
62 | 29/05/2020 | Symptoms: Biologics | OP-101 | Orpheris | June 2020 | Drug was originally being developed in arthritis but is now being expanded in the hope it can help in the pandemic. “The hydroxyl dendrimer component of OP-101 enables targeting to reactive macrophages, which are responsible for hyperinflammation, lung injury, and multi-organ failure caused by COVID-19. OP-101 normalizes reactive macrophages, shuts down the cytokine cascade and reduces oxidative stress to arrest hyperinflammation." | Received FDA approval for a Phase II clinical trial | https://www.fiercebiotech.com/biotech/after-passing-safety-hurdle-orpheris-kickstarts-covid-19-cytokine-storm-efficacy-test | ||||||||||||||||||||||||||||
63 | 18/04/2020 | Symptoms: Biologics | Tissue Plasminogen Activator | N/A | TBD | Team from the MIT have simualted the result of treating patients with ARDS with tPA (Tissue Plasminogen Activator) and predicted a reduced mortality of 47.6% [tTPA] vs. 71.0% [no tPA]. | Only mathematical predictions | https://wjes.biomedcentral.com/articles/10.1186/s13017-020-00305-4 | ||||||||||||||||||||||||||||
64 | 07/05/2020 | Symptoms: Biologics | otilimab | GSK | May/June 2020 | A monoclonal antibody already in GSK's pipeline which is anti-GM-CSF (granulocyte macrophage colony-stimulating factor) and is a “potential treatment for patients who have been hospitalised with severe pulmonary complications related to COVID-19.” | None yet - trials starting in May / June on 800 patients. | https://www.fiercebiotech.com/biotech/gsk-taps-experimental-arthritis-antibody-to-calm-cytokine-storm-hitting-covid-19-patients?mkt_tok=eyJpIjoiTW1NM00yUXdNR016TURnMSIsInQiOiJPRDJrUE5tRWxjZ0Vqd2duRWh0V2FIWWpTb3plamJWQmpHY1Y3VHRqSUlPZk5uN3krbTR1TkhsRDVyQlQ3OGduRFg3MllFTnNiRVB5alZOamErRE5VU0RkSVVkTGJvNFZoVHJYNmtyb2VDQ1F0T1hORU92b2NJdWNJWDlVcFNLWnBjUmlPWEh4WnZHRWJyYVRHeHcxTlE9PSJ9&mrkid=114702534 | ||||||||||||||||||||||||||||
65 | 16/03/2020 | Symptoms: Biologics | Kevzara | Regeneron / Sanofi | March 2020 | Rheumatoid Arthritis drug, humanised mABO that acts as an IL-6 receptor agonist that suppresses cytokine storm | As of 28th April the Phase III trial was modified to only treat critical patients, and remove the lowest dose which showed limited efficacy at Phase II. Symptoms improved in patients with severe symptoms but not in patients with mild symptoms, the trial thus failing to show clear efficacy. *** As of 7th July Trial shut down after finding no benefit on ventilated patients *** | N/A | https://www.pmlive.com/pharma_news/sanofi,_regeneron_launch_trials_of_arthritis_drug_kevzara_for_covid-19_1329326 https://www.fiercepharma.com/pharma/sanofi-regeneron-scale-back-kevzara-study-after-disappointing-results-severe-covid-19 https://research.gs.com/content/research/en/reports/2020/05/04/164ea47e-d1bc-4a13-8dc7-a8477192af92.html https://www.fiercepharma.com/pharma/sanofi-regeneron-s-kevzara-trial-covid-19-comes-to-a-screeching-halt-after-no-benefit-found?mkt_tok=eyJpIjoiWmprM1l6TTFaVGhtTmpjNSIsInQiOiJEY0dWYytDcXdyS2QxcVM2b3o1eHlKZUl5bDlaS3grZGdBaHFVMUN3YnJibGZ2MzRJdEVHQ09yVGxUZlwvQ1A3VXdjQ1wvMXdLVWVoZUw5Z2hTZE8wK1NPdFpRUllMaXhWYVg5Um9HUFM1aVJGZEtnWWZGMEpvVXFvd0gwYm1aUE5RUEFNRWhNSEJqMTRrY1V5WE9NOGJjZz09In0%3D&mrkid=114702534 | |||||||||||||||||||||||||||
66 | 20/03/20 | Symptoms: Biologics | Tocilizumab / Actemra | Roche | April 2020 (for Phase III in the US) | Rheumatoid Arthritis drug, humanised mABO that acts as an IL-6 receptor agonist that suppresses cytokine storm. Being trialled alone or with the flu drug Avigan. | Two trials ongoing in China (ChiCTR2000029765) and Italy (4 patients currently, up to 30 will be tested). As of 20th April 2020 the NHS have included tocilizumab in a UK based trial ("RECOVERY"). Early evidence of support in patients presenting with serious lung damage. US Phase III trial planned to start in April has been granted FDA approval (20th March). French study have gone to the press saying "positive results" but no pre-print available yet (28th April). On 19th June it was announced that Actemra failed to have an impact on patients with mild Covid-19 pneumonia. In late July further reports of failed trials were announced. | N/A | https://112.international/society/italy-claims-to-find-drugs-against-coronavirus-49605.html, https://www.channelnewsasia.com/news/business/china-approves-use-of-roche-arthritis-drug-for-covid-19-patients-12499492, https://www.straitstimes.com/world/europe/arthritis-drug-tocilizumab-shows-significant-promise-in-severe-covid-19-cases-study https://www.fiercepharma.com/pharma/roche-s-actemra-fails-italian-study-early-stage-covid-19-pneumonia?mkt_tok=eyJpIjoiWXpKa1kyRTROR0UxTVRNeCIsInQiOiJvY01oT2pRNHJidlk0SVZzWmxDTjd6bFJoSDB6SWVHNFwvbUg5ZFQzRzREekFrcUFTUmxlOFVwaUVnZlNjR3BuNlQwM1ZRaURHdkorRGtEdmY1ZkVjcjFVNDhQMm5SMnRNSzg5cE1iTUsrKzhmQTdTZG95cktyVGpUMGpcL25CK1Y0K1pUVW93aDkrQnNvVFBhWTJReW92dz09In0%3D&mrkid=114702534 | |||||||||||||||||||||||||||
67 | 02/04/2020 | Symptoms: Biologics | Lenzilumab | Humanigen | Ph III being planned | Anti-GM-CSF antibody to suppress cytokine storm | Phase III trial recruitment expected soon (3rd May) | https://www.proactiveinvestors.com/companies/news/916484/humanigen-s-lenzilumab-gets-fda-nod-for-emergency-use-on-compassionate-grounds-in-coronavirus-patients-916484.html | ||||||||||||||||||||||||||||
68 | 23/03/2020 | Symptoms: Biologics | Avastin / Bevacizumab | Genentech, Amgen (generic) | Feb / March 2020 | Anti VEGF-A which may be involved in severe inflammation of critical patients | Clinical trials underway in China | |||||||||||||||||||||||||||||
69 | 02/01/2020 | Symptoms: Biologics | Camrelizumab / AiRuiKa | Jiangsu HengRui Medicine | Anti-PD-1 immune checkpoint inhibitor - goal to prevent sepsis in severe infections | Clinical trial from China underway and due to report in April 2020 | https://clinicaltrials.gov/ct2/show/NCT04268537 | |||||||||||||||||||||||||||||
70 | 09/04/2020 | Symptoms: Biologics | CD24Fc | OncoImmune | PhIII being planned and FDA approved | CD24Fc fortifies an innate immune checkpoint against excessive inflammation caused by tissue-injuries | https://www.pharmaceutical-technology.com/news/oncoimmune-covid-19-therapy-trial/ | |||||||||||||||||||||||||||||
71 | 09/04/2020 | Symptoms: Biologics | Leronlimab | CytoDyn | PhIIb/III enrolling | CCR5 antagonist - suppression of cytokine storm | Promising data from 7 initial Covid-19 patients treated in New York, according to the developers (no control arm). | https://www.proactiveinvestors.com/companies/news/917046/cytodyn-says-severe-coronavirus-patients-treated-with-leronlimab-drug-show-significant-improvement-917046.html https://www.clinicaltrialsarena.com/news/cytodyn-leronlimab-covid-19-data/ | ||||||||||||||||||||||||||||
72 | 19/03/2020 | Symptoms: Biologics | Gimsilumab | Roivant | TBD - Ph II planned | Anti-GM-CSF, may help treat ARDS | Trial started on the 15th April 2020 | https://roivant.com/roivant-announces-development-of-anti-gm-csf-monoclonal-antibody-to-prevent-and-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19/ https://www.nytimes.com/reuters/2020/04/15/world/asia/15reuters-health-coronavirus-roivant.html | ||||||||||||||||||||||||||||
73 | 18/03/2020 | Symptoms: Biologics | Sylvant / Siltuximab | EUSA Pharma | Observational study in Italy in March | IL-6 Inhibitor | Promising early data from Italian study on 21 patients, run by the developer | https://www.fiercepharma.com/pharma/are-il-6-inhibitors-key-to-covid19-eusa-pharma-joins-sanofi-regeneron-rolling-out-trials https://www.europeanpharmaceuticalreview.com/article/116863/siltuximab-testing-a-potential-covid-19-therapy/ | ||||||||||||||||||||||||||||
74 | 04/05/2020 | Symptoms: Biologics | remestemcel-L | Mesoblast | Mar 2020 | Allogeneic mesenchymal stem cell derived treatment that has shown survival of 83% in small patient subset tested at Mount Sinai hospital. Larger trial is being planned. | Enrolling 300 patient trial | https://www.forbes.com/sites/alexknapp/2020/05/02/large-scale-clinical-trials-of-mesoblasts-stem-cell-treatment-for-covid-19-coronavirus-set-to-begin-soon/#38d6007f4086 | ||||||||||||||||||||||||||||
75 | 27/04/2020 | Symptoms: Biologics | Gelsolin / Rhu-pGSN | BioAegis Therapeutics | TBD - May 2020? | Recombinant human protein that is aiming to reduce lung injury | Animal data indicated Gelsolin can reduce symptoms of pneumonia after influenza infection. | https://www.biospace.com/article/releases/bioaegis-demonstrates-gelsolin-therapy-can-quell-the-cytokine-storm-and-promote-tissue-repair/ | ||||||||||||||||||||||||||||
76 | 14/04/2020 | Symptoms: Cell therapy | HLCM051 | Healios | TBD | Phase II study is underway evaluating use of somatic stem cell regenerative medicine therapy. | Company have agreed to include Covid-19 patients in ongoing trial. | https://www.prnewswire.com/news-releases/covid-19-ards-patients-added-to-healios-one-bridge-study-301039906.html | ||||||||||||||||||||||||||||
77 | 30/04/2020 | Symptoms: Cell therapy | CYNK-001 | Celularity | May 2020 | NK cell therapy | Ph I/ II trial being planned | https://clinicaltrials.gov/ct2/show/NCT04365101 | ||||||||||||||||||||||||||||
78 | 31/03/2020 | Symptoms: Cell therapy | Mesenchymal Stem Cells | VCANBio Cell & Gene Engineering | Anti-inflammatory therapy | Early trial ongoing | ||||||||||||||||||||||||||||||
79 | 01/05/2020 | Symptoms: Cell therapy | MultiStem Therapy | Athersys | May 2020 | "MultiStem® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy potential for multidimensional therapeutic impact may distinguish it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. MultiStem represents a unique "off-the-shelf" stem cell product candidate that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression." | FDA approval received to start Phase II /III trial in early May | https://www.businesswire.com/news/home/20200501005131/en/Athersys-University-Hospitals-Cleveland-Medical-Center-Announce | ||||||||||||||||||||||||||||
80 | 16/06/2020 | Symptoms: Small molecule | Dexamethasone | Multiple - off patent generic | Apr 2020 | Small molecule steroid - off patent therefore cheap and readily available. | On 16th June UK RECOVERY trial reported dexamethasone resulted in reduction in death rate of patients on ventilators by 1/3rd. 1 patient saved for every 8 on a ventilator. Reduced death rate by 1/5th in patients who were on oxygen only. Precise mechanism is not fully understood but steroids reduce inflammation, therefore may supress over-reaction of the immune system that causes secondary damage in response to the virus. | https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_final.pdf | ||||||||||||||||||||||||||||
81 | 21/04/2020 | Symptoms: Small molecule | Ultomiris | Alexion | May 2020 | Complement C5 inhibitor Ultomiris (ravulizumab) is already approved to treat paroxysmal nocturnal haemoglobinuria (PNH) in Europe, the US and Japan, and in the US for atypical haemolytic uremic syndrome (aHUS), and has just been cleared by the FDA for testing in COVID-19. | The study will enrol around 270 patients who have been hospitalised with severe COVID-19 symptoms, including pneumonia and acute respiratory distress syndrome (ARDS), across countries with a high number of coronavirus cases, says the company. | https://www.pmlive.com/pharma_news/alexion_will_test_rare_disease_drug_ultomiris_in_severe_covid-19_1338682 | ||||||||||||||||||||||||||||
82 | 31/03/2020 | Symptoms: Small molecule | Colchicine | Takeda, Hikma | Apr 2020 | Tubulin disruption to reduce cytokine storm | US Trial being planned that involves 6,000 patients being treated at home after being posted the drug. | https://www.physiciansweekly.com/anti-inflammatory-drug-colchicine-on-deck-for-covid-19/ https://www.livescience.com/covid-19-anti-inflammatory-drug-colchicine-study.html | ||||||||||||||||||||||||||||
83 | 19/05/2020 | Symptoms: Small molecule | Alvesco (Ciclesonide) | Covis Pharma | May 2020 | FDA have given regulatory approval for a Phase III trial to test inhbaled asthma drug in Covid-19 patients. | Alvesco is a glucocorticoid indicated for the long-term treatment of asthma as maintenance therapy in adults and adolescents 12 years of age and older in the U.S. and over 6 years of age in Canada. | https://www.prnewswire.com/news-releases/covis-pharma-bv-initiates-phase-3-clinical-trial-of-alvesco-ciclesonide-inhaler-for-the-treatment-of-covid-19-301061105.html | ||||||||||||||||||||||||||||
84 | 18/03/2020 | Symptoms: Small molecule | Methylprednisolone | Feb 2020 | "Rationale for the use of corticosteroids is to decrease the host inflammatory responses in the lungs, which may lead to acute lung injury and acute respiratory distress syndrome (ARDS). However, this benefit may be outweighed by adverse effects, including delayed viral clearance and increased risk of secondary infection.Use of steroids in treatment of ARDS - however data is conflicting." | US clinical trial ongoing, Chinese trial ongoing | N/A | https://clinicaltrials.gov/ct2/show/NCT04273321 https://jamanetwork.com/journals/jama/fullarticle/2764727 | ||||||||||||||||||||||||||||
85 | 22/02/2020 | Symptoms: Small molecule | Gilenya / Fingolimod | Novartis | February 2020 | A sphingosine 1-phosphate receptor modulator that may keep certain white blood cells (lymphocytes) from leaving the lymph nodes. Used in MS where stops lymphocytes crossing the blood-brain barrier, where they would further damage nerve cells. | 30 patient Phase II trial due to report in July | https://clinicaltrials.gov/ct2/show/NCT04280588 | ||||||||||||||||||||||||||||
86 | 17/03/2020 | Symptoms: Small molecule | Losartan | Generic | April 2020 | Generic blood pressure medication - may block ACE2 Receptors | Controversial area with some researchers believing may make patients worse. University of Minnesota have started a trial on 200 patients with the goal to reduce lung injury. | https://clinicaltrials.gov/ct2/show/NCT04312009 https://www.twincities.com/2020/04/21/umn-launches-two-coronavirus-trials-using-blood-pressure-medication-losartan/ | ||||||||||||||||||||||||||||
87 | 09/04/2020 | Symptoms: Small Molecule | Aviptadil | Relief Therapeutics | April 2020 | IL-6 Inhibitor, previously approved for other conditions | Trial enrolling for patients already on mechanical ventilation in Philadelphia | https://www.businesswire.com/news/home/20200409005265/en/Relief-Therapeutics-RLFSIX-Drug-Aviptadil-Enters-FDA | ||||||||||||||||||||||||||||
88 | 04/05/2020 | Symptoms: Small Molecule | Canakinumab | Novartis | May 2020 | interleukin-1β inhibitor | Novartis intends to recruit around 450 patients into the study at sites in France, Germany, Italy, Spain, UK and the US, who will be treated with either canakinumab or placebo on top of standard care for COVID-19. | http://www.pmlive.com/pharma_news/novartis_to_test_canakinumab_for_covid-19,_as_il-6_trial_disappoints_1339267 | ||||||||||||||||||||||||||||
89 | 08/04/2020 | Symptoms: Small Molecule | Selinexor / Xpovio | Karyopharm | Inhibitor of SINE which disrupts viral replication as well as having anti-inflammatory effects. | Has been shown in vitro to disrupt viral replication for other viruses. Anti-cancer drug for multiple myeloma. | https://www.targetedonc.com/view/a-global-randomized-trial-planned-for-selinexor-to-treat-covid19 | |||||||||||||||||||||||||||||
90 | 01/04/2020 | Symptoms: Small Molecule | SNG001 | Synairgen | April 2020 | Drug is an inhaled formulation of interferon-beta-1a — that has previously shown to be safe and effective in improving lung function in asthma patients with a respiratory viral infection in a pair of Phase II trials. | Reports breaking on 20th July of small trial of 100 patients results in 79% reduced risk of need for invasive ventilation | N/A | https://endpts.com/the-race-to-develop-covid-19-drugs-and-vaccines-is-on-heres-whats-happening-in-the-uk/?utm_medium=email&utm_campaign=942%20Wednesday%20April%201st%20-%20Expert%20hears%20crickets%20while%20FDA%20promises%20speedy%20Covid-19%20responses%20Trump%20has%20found%20another%20unproven%20coronavirus%20drug%20to%20love&utm_content=942%20Wednesday%20April%201st%20-%20Expert%20hears%20crickets%20while%20FDA%20promises%20speedy%20Covid-19%20responses%20Trump%20has%20found%20another%20unproven%20coronavirus%20drug%20to%20love+CID_a621eb0de9e5b716b2e758fded5174cf&utm_source=ENDPOINTS%20emails&utm_term=The%20race%20to%20develop%20Covid-19%20drugs%20and%20vaccines%20is%20on%20%20heres%20whats%20happening%20in%20the%20UK | |||||||||||||||||||||||||||
91 | 03/04/2020 | Symptoms: Small Molecule | Jakavi / Ruxolitinib | Novartis / Incyte | April 2020 | Jakavi is a JAK1 / JAK2 Kinase inhibitor that may have benefits in suppressing the cytokine storm in critically ill patients. Jakavi is used today to suppress the immune system in conditions such as Graft Versus Host Disease (GVHD) and Myelofibrosis | Approved drug for other conditions (polycythemia and myelofibrosis).Side effects can be serious (decrease in blood count and infections). Phase III trial enrolling as of 20th April 2020. | N/A | https://www.novartis.com/news/media-releases/novartis-announces-plan-initiate-clinical-study-jakavi-severe-covid-19-patients-and-establish-international-compassionate-use-program https://www.pharmaceutical-technology.com/news/incyte-ruxolitinib-covid-19-trial/ | |||||||||||||||||||||||||||
92 | 09/04/2020 | Symptoms: Small Molecule | tofacitinib | Pfizer | April (Ph II) | Hypothesis is JAK inhibition could mitigate systemic and alveolar inflammation in patients with COVID-19-related pneumonia by inhibiting essential cytokine signaling involved in immune-mediated inflammatory response that could lead to damage of the lungs, resulting in acute respiratory distress syndrome | Phase II study in Italy planned for middle of April | TBD | https://press.pfizer.com/press-release/pfizer-advances-battle-against-covid-19-multiple-fronts | |||||||||||||||||||||||||||
93 | 14/04/2020 | Symptoms: Small Molecule | Virazole / ribavirin | Bausch Health | May 2020 | VIRAZOLE is currently approved in several countries around the world, including the United States and Canada, for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Because ribavirin is a synthetic nucleoside that works to stop viral replication, VIRAZOLE may be effective in reducing the severity of COVID-19 infection. | As of mid April a trial in Canada was due to begin in a few weeks | https://ir.bauschhealth.com/news-releases/2020/04-13-2020-120008693 | ||||||||||||||||||||||||||||
94 | 14/04/2020 | Symptoms: Small Molecule | Calquence / acalabrutinib | AstraZeneca | April / May 2020 | Calquence is a next-generation, highly selective BTK inhibitor currently used to treat certain types of blood cancers. The BTK pathway may be involved in producing inflammatory cytokines that contribute to the cytokine storm. | Trial expected to open for enrollment in "the coming days" - reported 14th April 2020. | http://www.pharmatimes.com/news/az_to_test_calquence_for_covid-19_1338257 | ||||||||||||||||||||||||||||
95 | 09/04/2020 | Symptoms: Small Molecule | Vazegepant | Biohaven | April 2020 | an intranasal, high-affinity calcitonin gene-related peptide (CGRP) receptor antagonist, for the treatment of COVID-19 infection associated pulmonary complications | Currently in Phase III for other indications | https://www.prnewswire.com/news-releases/biohaven-receives-fda-may-proceed-letter-to-begin-phase-2-trial-of-intranasal-vazegepant-to-treat-lung-inflammation-after-covid-19-infection-301037998.html | ||||||||||||||||||||||||||||
96 | 14/04/2020 | Symptoms: Small Molecule | EPAspire™ | SLA Pharma | April 2020 | EPAspire™ is a unique, novel oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules that is delivered to the gut at optimal pH allowing maximal absorption. EPAspire™ is currently in a clinical trial in Europe for the treatment of familial adenomatous polyposis (FAP). Proprietary data from the FAP trials suggests it suppresses expression of inflammatory cytokines believed to contribute to the progression of COVID-19 symptoms. | Currently in Ph III for other indications. | https://www.businesswire.com/news/home/20200414005445/en/KD-Pharma-Group-SLA-Pharma-Initiate-Clinical | ||||||||||||||||||||||||||||
97 | 09/04/2020 | Symptoms: Small Molecule | Anakinra / Emapalumab | Swedish Orphan Biovitrum | May 2020 | Targets the IL-1 system. | TBD | https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30082-5/fulltext | ||||||||||||||||||||||||||||
98 | 16/04/2020 | Symptoms: Small Molecule | tradipitant | Vanda Pharmaceuticals | April 2020 | Tradipitant is a neurokinin-1 receptor (NK-1R) antagonist licensed by the company from Eli Lilly. The drug is being developed to treat gastroparesis, motion sickness, and atopic dermatitis. | Phase III trial started April 2020 | https://www.clinicaltrialsarena.com/news/vanda-tradipitant-covid-19-trial/ | ||||||||||||||||||||||||||||
99 | 15/04/2020 | Symptoms: Small Molecule | DAS181 | Ansun Pharma | April 2020 | "DAS181 is a recombinant sialidase protein that cleaves sialic acid located on the surface of epithelial cells lining the human respiratory tract. Many different viruses use sialic acid as a receptor for infecting the epithelial cells, and treatment with DAS181 can therefore block virus entry and prevent viral infection and spread. The drug has demonstrated antiviral activity against multiple sialic acid-dependent viruses, which makes it uniquely suitable as a broad-spectrum treatment for many different respiratory viral infections. DAS181 is delivered in a nebulized formulation using Aerogen® Solo aerosol drug delivery technology." | Small study being recruited for with 22 patients. Very early experimental study reporting promising data in early April. | https://www.biospace.com/article/releases/ansun-biopharma-enrolls-first-patient-in-proof-of-concept-trial-of-das181-for-the-treatment-of-covid-19/ | ||||||||||||||||||||||||||||
100 | 20/04/2020 | Symptoms: Small Molecule | DN-TNF | Inmune Bio | Summer 2020? | “DN-TNF targets one of the main cytokines involved in cytokine storm without causing immunosuppression. The trial targets patients not yet in ICU or on mechanical ventilation in an attempt to keep them from needing these scarce resources.” | Trial being planned as of early Mary 2020 | https://www.globenewswire.com/news-release/2020/04/20/2018642/0/en/INmune-Bio-Inc-Announces-Initiation-of-Clinical-Program-Targeting-Soluble-TNF-to-Determine-if-the-Company-s-TNF-Inhibitor-DN-TNF-Platform-May-Prevent-Complications-of-Cytokine-Stor.html |